Journal of the Korean Society of Food Science and Nutrition (한국식품영양과학회지)

The Korean Society of Food Science and Nutrition (한국식품영양과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Dietary Tea Polyphenol on Tumor Growth Inhibition by Cisplatin in EMT6 Breast Tumor-bearing Mice

유방암 세포(EMT6) 이식 마우스에서 녹차폴리페놀 음용이 시스플라틴의 암 조직 성장 억제에 미치는 영향

  • Lee, Byoung-Rai (Dept. of Biochemistry, College of Medicine, Chosun University) ;
  • Cho, Jung-Il (Dept. of Food Nutrient and Culinary, Chosun College of Science & Technology) ;
  • Park, Pyoung-Sim (Institute of Medical Science, Chosun University)
  • 이병래 (조선대학교 의과대학 생화학교실) ;
  • 조정일 (조선이공대학교 식품영양조리과학과) ;
  • 박평심 (조선대학교 의학연구원)
  • Received : 2013.09.04
  • Accepted : 2013.11.25
  • Published : 2014.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study is to evaluate the effects of green tea polyphenol (GTP) on anticancer treatment with cisplatin (CP), using both an in vitro cell culture model and an in vivo mouse model of established breast tumor. Mouse breast cancer cells (EMT6) were treated with or without GTP and CP followed by determination of the cell viability using an MTT assay. The relative cell viability of CP treated EMT6 cells was 96% at a 20 ${\mu}g/mL$ concentration of cisplatin; however, in combination with GTP (50 ${\mu}g/mL$), the cell viability decreased to 20% at the same concentration of CP (20 ${\mu}g/mL$). For the in vivo study, EMT6 cells were inoculated into Balb/c mice for the establishment of a tumor-bearing mice model. The tumor-bearing mice were treated with CP (5 mg/kg. i.p.) with or without dietary GTP (0.2% drinking water). Tumor growth was monitored by a measurement of tumor size using a digital caliper, and nephrotoxicity was determined by enzymatic and histological examinations. The levels of p53 and caspase-3 in tumor tissues were examined by a Western blot. In tumor-bearing mice treated with GTP plus CP, the increment of tumor volume showed a significant reduction, compared with CP or GTP alone. The levels of p53 and cleaved caspase-3 (caspase-3/p17) in tumor tissues of tumor-bearing mice were increased by CP and GTP compared to CP alone. In CP treated tumor-bearing mice, ${\gamma}$-glutamyltranspeptidase (GGT) and alkaline phosphatase (AP) activities were decreased, and marked tubular necrosis and dilatation were observed in the kidney. CP-induced enzymatic and histopathological changes in the kidney of tumor-bearing mice were reduced by combinations of GTP with CP. The results of these experiments demonstrated that dietary GTP has a potentiating effect on CP anti-tumor activity and a protective effect against CP-induced renal dysfunction. Therefore, GTP may be used as a modulator in anticancer treatment with CP.

본 연구는 녹차폴리페놀이 시스플라틴의 항암작용과 신장 독성에 미치는 영향을 유방암 세포(EMT6)와 암세포 이식마우스를 이용하여 in vitro와 in vivo 실험으로 관찰하였다. 배양한 EMT6 세포에서 녹차폴리페놀은 시스플라틴에 의한 세포 독성을 증가시켰다. 마우스에 EMT6 세포를 주사하여 유발된 종양의 크기가 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 작았고, 종양조직 p53와 caspase-3 활성화가 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 높았으며, 신장 GGT와 AP 활성은 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 높았고, 신장 조직학적 소견에서 신세뇨관 확장과 괴사가 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 낮았다. 이상의 결과 녹차폴리페놀은 EMT6 유방암 세포를 이용한 in vitro 및 in vivo 실험에서 시스플라틴의 항암작용을 증강시키면서 신장에 대한 독성 부작용은 감소시키는 효과가 있는 것으로 추측된다. 녹차폴리페놀의 시스플라틴 항암작용 증강과 신장 독성 억제 및 감소 효과는 시스플라틴에 의한 암 치료 시 화학요법제의 보조제로서 이용가치가 있는 것으로 생각되며, 항암화학요법제에 대한 보조제로의 개발을 위해서는 대규모 동물실험을 통한 효과 입증 및 부작용에 대한 실험과 임상연구가 뒷받침되어야 할 것으로 사료된다.

Keywords

References

  1. Matsuyama R, Reddy S, Smith TJ. 2006. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24: 3490-3496. https://doi.org/10.1200/JCO.2005.03.6236
  2. Lonning PE. 2010. Molecular basis for therapy resistance. Mol Oncol 4: 284-300. https://doi.org/10.1016/j.molonc.2010.04.005
  3. Sancho-Martinez SM, Prieto-Garcia L, Prieto M, Lopez- Novoa JM, Lopez-Hernandez FJ. 2012. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 136: 35-55. https://doi.org/10.1016/j.pharmthera.2012.07.003
  4. Bartelink H, Schellens JH, Verheij M. 2002. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 38: 216-222. https://doi.org/10.1016/S0959-8049(01)00363-X
  5. Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O. 2006. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 4: 211-219. https://doi.org/10.1016/S1479-666X(06)80062-4
  6. Vogl DT, Stadtmauer EA. 2006. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant 37: 985-987. https://doi.org/10.1038/sj.bmt.1705366
  7. Mishra BB, Tiwari VK. 2011. Natural products: an evolving role in future drug discovery. Eur J Med Chem 46: 4769-4807. https://doi.org/10.1016/j.ejmech.2011.07.057
  8. Yang CS, Wang X. 2010. Green tea and cancer prevention. Nutr Cancer 62: 931-937. https://doi.org/10.1080/01635581.2010.509536
  9. Gupta S, Hussain T, Mukhtar H. 2003. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cells cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410: 177-185. https://doi.org/10.1016/S0003-9861(02)00668-9
  10. Singh M, Bhui K, Singh R, Shukla Y. 2013. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci 93: 7-16. https://doi.org/10.1016/j.lfs.2013.02.001
  11. Luo T, Wang J, Yin Y, Hua H, Jing J, Sun X, Li M, Zhang Y, Jiang Y. 2010. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 12: R8. doi: 10.1186/bcr2473.
  12. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ. 1975. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59: 647-659.
  13. Jordan P, Carmo-Fonseca M. 2000. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229-1235. https://doi.org/10.1007/PL00000762
  14. Hartmann JT, Lipp HP. 2003. Toxicity of platinum compounds. Expert Opin Pharmacother 4: 889-901. https://doi.org/10.1517/14656566.4.6.889
  15. Shamseddine AI, Farhat FS. 2011. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 57: 468-487. https://doi.org/10.1159/000334093
  16. Shrubsole MJ, Lu W, Chen Z, Shu XO, Zheng Y, Dai Q, Cai Q, Gu K, Ruan ZX, Gao YT, Zheng W. 2009. Drinking green tea modestly reduces breast cancer risk. J Nutr 139:310-316.
  17. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. 2007. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 245: 232-241. https://doi.org/10.1016/j.canlet.2006.01.027
  18. Sladowski D, Steer SJ, Clothier RH, Balls M. 1993. An improved MTT assay. J Immunol Methods 157: 203-207. https://doi.org/10.1016/0022-1759(93)90088-O
  19. Tenenhouse HS, Scriver CR, Vizel EJ. 1980. Alkaline phosphatase activity does not mediate phosphate transport in the renal-cortical brush-border membrane. Biochem J 190: 473-476.
  20. Tate SS, Meister A. 1985. $\gamma$-Glutamyl transpeptidase from kidney. Methods Enzymol 113: 400-419. https://doi.org/10.1016/S0076-6879(85)13053-3
  21. Nessa MU, Beale P, Chan C, Yu JQ, Huq F. 2012. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res 32: 53-59.
  22. Chan MM, Soprano KJ, Weinstein K, Fong D. 2006. Epigallocatechin- 3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207: 389-396. https://doi.org/10.1002/jcp.20569
  23. Periasamy VS, Alshatwi AA. 2013. Tea polyphenols modulate antioxidant redox system on cisplatin-induced reactive oxygen species generation in a human breast cancer cell. Basic Clin Pharmacol Toxicol 112: 374-384. https://doi.org/10.1111/bcpt.12035
  24. Graham HN. 1992. Green tea composition, consumption, and polyphenol chemistry. Prev Med 21: 334-350. https://doi.org/10.1016/0091-7435(92)90041-F
  25. Yee MS, Blakley BW, Begleiter A, Leith M. 2008. Delayed sodium thiosulphate administration reduces cisplatin efficacy on mouse EMT6 tumour cells in vitro. J Otolaryngol Head Neck Surg 37: 638-641.
  26. Fraser M, Chan SL, Chan SS, Fiscus RR, Tsang BK. 2006. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25: 2203-2212. https://doi.org/10.1038/sj.onc.1209251
  27. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. 2003. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22: 4851-4859. https://doi.org/10.1038/sj.onc.1206708
  28. Khan SA, Priyamvada S, Khan W, Khan S, Farooq N, Yusufi AN. 2009. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol Res 60:382-391. https://doi.org/10.1016/j.phrs.2009.07.007
  29. Fatima S, Arivarasu NA, Mahmood R. 2007. Vitamin C attenuates cisplatin-induced alterations in renal brush border membrane enzymes and phosphate transport. Hum Exp Toxicol 26: 419-426. https://doi.org/10.1177/0960327106072389
  30. Ateşşahín A, Ceríbaşi AO, Yuce A, Bulmus O, Cikim G. 2007. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100: 121-126.
  31. El-Mowafy AM, Al-Gayyar MM, Salem HA, El-Mesery ME, Darweish MM. 2010. Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 17: 1067-1075. https://doi.org/10.1016/j.phymed.2010.08.004

Cited by

  1. The Impact of Herbal Infusion Consumption on Oxidative Stress and Cancer: The Good, the Bad, the Misunderstood vol.25, pp.18, 2020, https://doi.org/10.3390/molecules25184207